Byonyks
Farrukh Usman is an accomplished entrepreneur and software engineering expert with extensive experience in the medical device industry and software development. As the Founder and CEO of Byonyks Medical Devices since January 2019, Farrukh has significantly contributed to the commercialization of peritoneal dialysis machines in the U.S. Previously, roles included Board Observer at Gaper, Consultant at Sunrise Labs, Inc., and leadership positions as Head of Software Engineering at Insulet Corporation and Beacon Power LLC. Early career experience includes roles at DEKA Research & Development, Mentor Graphics, and ComputerEye, focusing on embedded systems and software engineering. Farrukh holds a Master's degree in Management from Harvard University and a Master of Science in Computer Science from Lahore University of Management Sciences.
This person is not in any teams
This person is not in any offices
Byonyks
Byonyks has pioneered the world’s first affordable Bloodless Dialysis machine, transforming care for kidney failure patients. Globally, over eight million people with kidney disease lack dialysis access—a costly, invasive, and time-consuming treatment that filters blood when kidneys fail. Many of these individuals face life-threatening consequences due to the lack of proper care. Byonyks addresses this critical issue with its Bloodless Dialysis machine; a safe, effective, portable, and non-invasive solution that’s more affordable than existing options. Our technology empowers patients to perform dialysis at home, overnight, while they sleep, allowing them to maintain their daily work and family responsibilities. The needle-free approach also reduces the risk of chronic infections such as HIV and Hepatitis C. Headquartered in the USA and South Asia, Byonyks is a medical device startup founded by Harvard/MIT graduates and industry experts. Our core team’s expertise contributes to over half of the operational peritoneal dialysis machines worldwide. The groundbreaking Bloodless Dialysis machine has saved multiple lives in South Asia and is currently under FDA review—a pivotal step towards making accessible kidney care a global reality.